Congenital fibrinogen disorders: a retrospective clinical and genetic analysis of the Prospective Rare Bleeding Disorders Database.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
29 Jan 2024
Historique:
accepted: 13 01 2024
received: 15 11 2023
revised: 11 01 2024
medline: 30 1 2024
pubmed: 30 1 2024
entrez: 29 1 2024
Statut: aheadofprint

Résumé

Congenital fibrinogen deficiency (CFD) is a rare bleeding disorder caused by mutations in FGA, FGB and FGG. We sought to comprehensively characterize patients with CFD using PRO-RBDD (Prospective Rare Bleeding Disorders Database). Clinical phenotypes, laboratory and genetic features were investigated using retrospective data from the PRO-RBDD. Patients were classified from asymptomatic to grade III based on their bleeding severity. In addition, FGA, FGB and FGG were sequenced to find causative variants. A total of 166 CFD cases from 16 countries were included, of whom 123 (30 afibrinogenemia, 33 hypofibrinogenemia, 55 dysfibrinogenemia, 5 hypodysfibrinogenemia) were well characterized. Considering the previously established factor activity and antigen level thresholds, bleeding severity was correctly identified in 58% of cases. The rate of thrombotic events among afibrinogenemic and hypofibrinogenemic patients were relatively similar (11% and 10%) and surprisingly higher than in dysfibrinogenemic cases. The rate of spontaneous abortions among 68 pregnancies was 31%, including 86% in dysfibrinogenemic women and 14% with hypofibrinogenemia. 86 patients received treatment (69 on-demand and/or 17 on prophylaxis), fibrinogen concentrates being the most frequently used product. Genetic analysis was available for 91 cases and 41 distinct variants were identified. Hotspot variants (FGG, p.Arg301Cys/His and FGA, p.Arg35Cys/His) were present in 51% of dysfibrinogenemia. Obstetric complications were commonly observed in dysfibrinogenemia. This large multicenter study provided a comprehensive insight into the clinical, laboratory and genetics of patients with CFDs. We conclude that bleeding severity grades were in agreement with the established factor activity threshold in nearly half of the cases with quantitative defects.

Identifiants

pubmed: 38286442
pii: 514755
doi: 10.1182/bloodadvances.2023012186
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 American Society of Hematology.

Auteurs

Samin Mohsenian (S)

Università degli Studi di Milano, Department of Pathophysiology and Transplantation, Milan, Italy.

Roberta Palla (R)

Università degli Studi di Milano, Milan, Italy.

Marzia Menegatti (M)

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Andrea Cairo (A)

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, A. Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy.

Anna Lecchi (A)

Fondazione IRCCS Ospedale Maggiore Policlinico Milano, Saronno, Italy.

Alessandro Casini (A)

Hôpitaux Universitaire de Genève, Geneva, Switzerland.

Marguerite Neerman-Arbez (M)

University of Geneva Faculty of Medicine, Geneva, Switzerland.

Rosanna Asselta (R)

Humanitas University, Pieve Emanuele, Italy.

Sara Scardo (S)

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy.

Simona Maria Siboni (SM)

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Jan Blatný (J)

University Hospital and Masaryk University Brno, Brno, Czech Republic.

Ondrej Zapletal (O)

University Hospital and Masaryk University Brno, Brno, Czech Republic.

Jean-Francois Schved (JF)

Montpellier University Hospital, Montpellier, France.

Muriel Giansily-Blaizot (M)

CHU de Montpellier, Montpellier, France.

Susan Halimeh (S)

Coagulation Center Rhine-Ruhr.

Ayman Daoud (A)

Hematology Research Center GmbH, Duisburg, Germany.

Helen Platokouki (H)

"Aghia Sophia" Children's Hospital, Athens, Greece.

Helen Pergantou (H)

Agia Sofia Children's Hospital, Athens, Greece.

Roger E G Schutgens (REG)

UMC Utrecht, Utrecht, Netherlands.

Monique Van Haaften-Spoor (MV)

Center for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, University Medical Center Utrecht, Utrecht University,, Utrecht, Netherlands.

Paul Brons (P)

Radboudumc, Nijmegen, Netherlands.

Britta A P Laros-van Gorkom (BAP)

Radboud umc, Nijmegen, Netherlands.

Elise Van Pinxten (EV)

Department of hematology, Radboud University Medical Center, Nijmegen, Netherlands.

Munira Borhany (M)

National Institute of Blood Disease & Bone Marrow Transplantation.

Naveena Fatima (N)

National Institute of Blood Disease & Bone Marrow Transplantation.

Danijela Mikovic (D)

National Blood Transfusion Institute, Belgrade, Serbia.

Marko Saracevic (M)

Blood Transfusion Institute of Serbia, Belgrade, Serbia.

Gül Nihal Özdemir (GN)

Istinye University, Pediatric Hematology Department, Istanbul, Arkansas, Turkey.

Yılmaz Ay (Y)

University of Health Sciences, Kartal Dr Lütfi Kırdar City Hospital, Istanbul, Turkey.

Michael Makris (M)

University of Sheffield, Sheffield, United Kingdom.

Caryl Lockley (C)

University of Sheffield, Sheffield, United Kingdom.

Andrew D Mumford (AD)

University of Bristol, UK, Bristol, United Kingdom.

Andrew Harvey (A)

Bristol Haematology and Oncology Centre, Bristol, United Kingdom.

Steven Kenneth Austin (SK)

St George's University Hospitals NHS Foundation Trust, London, United Kingdom.

Amy D Shapiro (AD)

Indiana Hemophilia & Thrombosis Center, Inc, Indianapolis, Indiana, United States.

Adrianna Williamson (A)

Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, United States.

Catherine McGuinn (C)

Weill Cornell Medicine, New York, NY USA, New York, New York, United States.

Ilene Goldberg (I)

Weill Cornell Medicine, New York, New York, United States.

Philippe de Moerloose (P)

University Hospital of Geneva, Geneva, Switzerland.

Flora Peyvandi (F)

Università degli Studi di Milano, Department of Pathophysiology and Transplantation, and Fondazione Luigi Villa, Milan, Italy., Milan, Italy.

Classifications MeSH